Cargando…

Immunological and Clinical Effects of Vaccines Targeting p53-Overexpressing Malignancies

Approximately 50% of human malignancies carry p53 mutations, which makes it a potential antigenic target for cancer immunotherapy. Adoptive transfer with p53-specific cytotoxic T-lymphocytes (CTL) and CD4(+) T-helper cells eradicates p53-overexpressing tumors in mice. Furthermore, p53 antibodies and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vermeij, R., Leffers, N., van der Burg, S. H., Melief, C. J., Daemen, T., Nijman, H. W.
Formato:	Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2011
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3085500/ https://www.ncbi.nlm.nih.gov/pubmed/21541192 http://dx.doi.org/10.1155/2011/702146

Ejemplares similares

Immunologic aspect of ovarian cancer and p53 as tumor antigen
por: Nijman, HW, et al.
Publicado: (2005)

Potential Target Antigens for a Universal Vaccine in Epithelial Ovarian Cancer
por: Vermeij, Renee, et al.
Publicado: (2010)

Clinical and Immunological Effects of p53-Targeting Vaccines
por: Zhou, Shan, et al.
Publicado: (2021)

Corrigendum: Clinical and immunological effects of p53-targeting vaccines
por: Zhou, Shan, et al.
Publicado: (2023)

A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer
por: Dijkgraaf, Eveline M., et al.
Publicado: (2015)

Antibodies against p53 are associated with poor prognosis of colorectal cancer.
por: Houbiers, J. G., et al.
Publicado: (1995)

The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis
por: Gooden, M J M, et al.
Publicado: (2011)

Synergy between chemotherapy and cancer vaccination
por: van der Sluis, Tetje C., et al.
Publicado: (2015)

Tumor Eradication by Wild-type p53-specific Cytotoxic T Lymphocytes
por: Vierboom, Michel P.M., et al.
Publicado: (1997)

Overexpression of p53 protein during pancreatitis.
por: Maacke, H., et al.
Publicado: (1997)

p53 protein overexpression and allele loss of p53 gene in gastric adenocarcinoma.
por: Choi, S. W., et al.
Publicado: (1994)

Targeting p53 by small molecules in hematological malignancies
por: Saha, Manujendra N, et al.
Publicado: (2013)

Mutations in p53, p53 protein overexpression and breast cancer survival
por: Rossner, Pavel, et al.
Publicado: (2009)

p53 mutation, but not p53 overexpression, correlates with survival in head and neck squamous cell carcinoma.
por: Mineta, H., et al.
Publicado: (1998)

Regulation of immunological tolerance by the p53-inhibitor iASPP
por: Akama-Garren, Elliot H., et al.
Publicado: (2023)

Prognostic significance of p53 overexpression and mutation in colorectal adenocarcinomas.
por: Smith, D. R., et al.
Publicado: (1996)

Educational paper: The expanding clinical and immunological spectrum of severe combined immunodeficiency
por: van der Burg, Mirjam, et al.
Publicado: (2011)

Interleukin-6 receptor and its ligand interleukin-6 are opposite markers for survival and infiltration with mature myeloid cells in ovarian cancer
por: Wouters, MCA, et al.
Publicado: (2015)

From Tumor Immunosuppression to Eradication: Targeting Homing and Activity of Immune Effector Cells to Tumors
por: Draghiciu, Oana, et al.
Publicado: (2011)

Overexpression of PDGFRA cooperates with loss of NF1 and p53 to accelerate the molecular pathogenesis of malignant peripheral nerve sheath tumors
por: Ki, D H, et al.
Publicado: (2017)

IDO and galectin-3 hamper the ex vivo generation of clinical grade tumor-specific T cells for adoptive cell therapy in metastatic melanoma
por: Melief, Sara M., et al.
Publicado: (2017)

p53 mutation and epidermal growth factor receptor overexpression in glioblastoma.
por: Yoon, K. S., et al.
Publicado: (2001)

Clinical and immunological effects of mRNA vaccines in malignant diseases
por: Heine, Annkristin, et al.
Publicado: (2021)

P59. Depleting the suppressors for the benefit of immunotherapy against cervical cancer
por: Draghiciu, O, et al.
Publicado: (2014)

MNAT1 is overexpressed in colorectal cancer and mediates p53 ubiquitin-degradation to promote colorectal cancer malignance
por: Zhou, Shan, et al.
Publicado: (2018)

Overexpression of DRAM enhances p53-dependent apoptosis
por: Takahashi, Masahiro, et al.
Publicado: (2013)

Identification of genes and pathways associated with cytotoxic T lymphocyte infiltration of serous ovarian cancer
por: Leffers, N, et al.
Publicado: (2010)

Overexpression of p53 in different subtypes of intestinal metaplasia and gastric cancer.
por: Wu, M. S., et al.
Publicado: (1998)

Overexpression of p53 mRNA in colorectal cancer and its relationship to p53 gene mutation.
por: el-Mahdani, N., et al.
Publicado: (1997)

p53 oncoprotein overexpression correlates with mutagen-induced chromosome fragility in head and neck cancer patients with multiple malignancies.
por: Gallo, O., et al.
Publicado: (1995)

Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy
por: Hanoteau, Aurelie, et al.
Publicado: (2019)

Gastric cancer with p53 overexpression has high potential for metastasising to lymph nodes.
por: Kakeji, Y., et al.
Publicado: (1993)

p53 mutations and overexpression in locally advanced breast cancers.
por: Faille, A., et al.
Publicado: (1994)

Prognostic significance of p53 overexpression in gastric and colorectal carcinoma.
por: Starzynska, T., et al.
Publicado: (1992)

Overexpression of p53 and long-term survival in colon carcinoma.
por: Auvinen, A., et al.
Publicado: (1994)

Tobacco, alcohol, and p53 overexpression in early colorectal neoplasia
por: Terry, Mary Beth, et al.
Publicado: (2003)

A cytohistological study of p53 overexpression in ovarian neoplasms
por: Choudhury, Monisha, et al.
Publicado: (2012)

Targeting of the Cancer-Associated Fibroblast—T-Cell Axis in Solid Malignancies
por: Harryvan, Tom J., et al.
Publicado: (2019)

Elevated serum CXCL16 is an independent predictor of poor survival in ovarian cancer and may reflect pro-metastatic ADAM protease activity
por: Gooden, M J M, et al.
Publicado: (2014)

Editorial: Cancer Prevention: Targeting Premalignant Epithelial Neoplasms in the Era of Cancer Immunotherapy and Vaccines
por: Çuburu, Nicolas, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_oqp2baoadoupjidsugbtu3f2tv